Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 15 of 15

List	Outcome	Time frame	Description
Primary	The RP2D of LB-100 when given in combination with standard doses of atezolizumab	up to 2 years
Secondary	Disease control rate	6 months	Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Secondary	Objective response rate	6 months	Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Secondary	Duration of overall response	up to 2 years	Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Secondary	Progression free survival	up to 2 years	Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Secondary	Overall survival	Assessed up to 2 years	The time from the first dose of study treatment to the time of death from any cause. Patients who are still alive at the time of analysis will be censored at the time of their last study assessment (for active patients) or at the last date know alive (for patients in follow-up).
Secondary	Observed plasma concentrations of LB-100, its active metabolite endothall and atezolizumab	Prior to initial dose, on day 1, day 2, day 3, day 8, day 15 and prior to second cycle. Each cycle is 21 days	Blood samples are obtained and plasma concentrations of LB-100, endothall and atezolizumab are measured
Secondary	Area under the plasma-time concentration curve of LB-100, its active metabolite endothall and atezolizumab	Prior to initial dose, on day 1, day 2, day 3, day 8, day 15 and prior to second cycle. Each cycle is 21 days	Blood samples are obtained and plasma concentrations of LB-100, endothall and atezolizumab are measured
Secondary	Elimination half-life of LB-100, its active metabolite endothall and atezolizumab	Prior to initial dose, on day 1, day 2, day 3, day 8, day 15 and prior to second cycle. Each cycle is 21 days	Blood samples are obtained and plasma concentrations of LB-100, endothall and atezolizumab are measured
Secondary	Total body clearance of LB-100, its active metabolite endothall and atezolizumab	Prior to initial dose, on day 1, day 2, day 3, day 8, day 15 and prior to second cycle. Each cycle is 21 days	Blood samples are obtained and plasma concentrations of LB-100, endothall and atezolizumab are measured
Secondary	The incidence and severity of adverse events	Up to 2 years	As assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Secondary	The incidence of dose-limiting toxicity	21 days	As assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Other	Serine/threonine hyperphosphorylation in peripheral white blood cells	Blood sample cycle 1 day 1. Each cycle is 21 days.	Western Blots to evaluate serine/threonine hyperphosphorylation in peripheral white blood cells
Other	Mismatch repair deficiency status	Before start of treatment and one on treatment biopsy at Cycle 3 day 3. Each cycle is 21 days	Immunohistochemistry for mismatch repair proteins
Other	Concentration of LB-100 and endothall in tumor tissue	On treatment biopsy at Cycle 3 day 3. Each cycle is 21 days	To evaluate pharmacodynamic biomarkers of LB-100

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06012734/registered

API reference For AI assistants